Interrogating the Significance of PARP1 Expression and PBRM1 Mutation as Biomarkers for Predicting the Response to Atezolizumab plus Bevacizumab or to Sunitinib in Patients with Clear Cell Renal Cell Carcinoma

Eur Urol. 2022 Sep;82(3):334-335. doi: 10.1016/j.eururo.2022.05.013. Epub 2022 Jun 7.

Authors

Javier Lanillos¹, María Santos¹, Carlos Valdivia¹, Alberto Mora¹, Cristina Rodríguez-Antona²

Affiliations

¹ Hereditary Endocrine Cancer Group, Human Cancer Genetics Programme, Spanish National Cancer Research Centre, Madrid, Spain.
² Hereditary Endocrine Cancer Group, Human Cancer Genetics Programme, Spanish National Cancer Research Centre, Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras, Madrid, Spain. Electronic address: crodriguez@cnio.es.

PMID: 35688666
DOI: 10.1016/j.eururo.2022.05.013

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Bevacizumab / therapeutic use
Biomarkers
Carcinoma, Renal Cell* / drug therapy
Carcinoma, Renal Cell* / genetics
Carcinoma, Renal Cell* / pathology
DNA-Binding Proteins / genetics
Humans
Kidney Neoplasms* / drug therapy
Kidney Neoplasms* / genetics
Kidney Neoplasms* / pathology
Mutation
Poly (ADP-Ribose) Polymerase-1 / genetics
Sunitinib / therapeutic use
Transcription Factors / genetics

Substances

Antibodies, Monoclonal, Humanized
Biomarkers
DNA-Binding Proteins
PBRM1 protein, human
Transcription Factors
Bevacizumab
atezolizumab
PARP1 protein, human
Poly (ADP-Ribose) Polymerase-1
Sunitinib